Positron emission tomography imaging of meningioma in clinical practice: Review of literature and future directions

Neurosurgery

Volumn 70, Issue 4, 2012, Pages 1033-1041

  Cornelius, Jan Frederick ^a   Josef Langen, Karl ^b   Stoffels, Gabriele ^b   Hänggi, Daniel ^a   Sabel, Michael ^a   Jakob Steiger, Hans ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Clinical management; Meningioma; Molecular imaging; Positron emission tomography; Surgical planning

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N'' TETRAACETIC ACID DEXTRO PHENYLALANYLTYROSINE OCTREOTIDE GA 68; ACETIC ACID C 11; ANTINEOPLASTIC AGENT; CARBON 11; CHOLINE C 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROTYROSINE F 18; GADOLINIUM 68; METHIONINE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMAGE ANALYSIS; MENINGIOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; POSITRON-EMISSION TOMOGRAPHY;

EID: 84858747596     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e31823bcd87     Document Type: Article

References (71)

1. Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol. 2010;99(3):379-391.
2. Gudjonsson O, Blomquist E, Lilja A, Ericson H, Bergström M, Nyberg G. Evaluation of the effect of high-energy proton irradiation treatment on meningiomas by means of 11C-L-methionine PET. Eur J Nucl Med. 2000;27 (12):1793-1799.
3. Pieper DR, Al-Mefty O, Hanada Y, Buechner D. Hyperostosis associated with meningioma of the cranial base: secondary changes or tumor invasion. Neurosurgery. 1999;44(4):742-746; discussion 746-747.
4. Caroli P, Nanni C, Rubello D, Alavi A, Fanti S. Non-FDG PET in the practice of oncology. Indian J Cancer. 2010;47(2):120-125.
5. Patel CN, Goldstone AR, Chowdhury FU, Scarsbrook AF. FDG PET/CT in oncology: "raising the bar". Clin Radiol. 2010;65(7):522-535.
6. Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49(3):480-508. (Pubitemid 351355215)
7. Pöpperl G, Götz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004;31(11):1464-1470. (Pubitemid 39592765)
8. Stockhammer F, Misch M, Horn P, Koch A, Fonyuy N, Plotkin M. Association of F18-fluoro-ethyl-tyrosin uptake and 5-aminolevulinic acid-induced fluorescence in gliomas. Acta Neurochir (Wien). 2009;151(11):1377-1383.
9. Tsuyuguchi N. Kinetic analysis of glucose metabolism by FDG-PET versus proliferation index of Ki-67 in meningiomas-comparison with gliomas. Osaka City Med J. 1997;43(2):209-223.
10. Wyss M, Hofer S, Bruehlmeier M, et al. Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol. 2009;95(1):87-93.
11. Wyss MT, Hofer S, Hefti M, et al. Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake. J Nucl Med. 2007;48(7):1047-1052. (Pubitemid 47052641)
12. Wyss MT, Spaeth N, Biollaz G, et al. Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP(L19), a marker of angiogenesis. J Nucl Med. 2007;48(4):608-614. (Pubitemid 47571418)
13. Nestle U, Weber W, Hentschel M, Grosu AL. Biological imaging in radiation therapy: role of positron emission tomography. Phys Med Biol. 2009;54(1):R1-R25.
14. Fanti S, Franchi R, Battista G, Monetti N, Canini R. PET and Pet-CT. State of the art and future prospects. Radiol Med. 2005;110(1-2):1-15.
15. Floeth FW, Sabel M, Ewelt C, et al. Comparison of (18)F-FET PET and 5-ALA fluorescence in cerebral gliomas. Eur J Nucl Med Mol imaging. 2010;38(4): 731-741.
16. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005;46(5):763-769.
17. De Langen AJ, van den Boogaart VE, Marcus JT, Lubberink M. Use of H2(15 O)-PET and DCE-MRI to measure tumor blood flow. Oncologist. 2008;13(6): 631-644. (Pubitemid 351904908)
18. Keiding S, Sørensen M, Munk OL, Bender D. Human (13)N-ammonia PET studies: the importance of measuring (13)N-ammonia metabolites in blood. Metab Brain Dis. 2010;25(1):49-56.
19. Donadon M, Bona S, Montorsi M, Torzilli G. FDG-PET positive granuloma of the liver mimicking local recurrence after hepatic resection of colorectal liver metastasis. Hepatogastroenterology. 2010;57(97):138-139.
20. Vos FJ, Bleeker-Rovers CP, Sturm PD, et al. 18F-FDG PET/CT for detection of metastatic infection in gram-positive bacteremia. J Nucl Med. 2010;51(8):1234-1240.
21. Lee TS, Ahn SH, Moon BS, et al. Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats. Nucl Med Biol. 2009;36(6):681-686.
22. Vaalburg W, Coenen HH, Crouzel C, et al. Amino acids for the measurement of protein synthesis in vivo by PET. Int J Rad Appl Instrum B. 1992;19(2):227-237.
23. Jacobs AH, Thomas A, Kracht LW, et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46(12):1948-1958. (Pubitemid 46657440)
24. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48(9): 1468-1481. (Pubitemid 47397397)
25. Murakami M, Imahori Y, Kimura S, et al. Positron emission tomography elucidates transport system and tumor proliferation in meningiomas. Oncol Rep. 2005;14(4):853-859.
26. Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, De Michele DJ. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology. 1987;164(2):521-526. (Pubitemid 17097978)
27. Cremerius U, Bares R, Weis J, et al. Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET. J Nucl Med. 1997;38(1):26-30. (Pubitemid 27026992)
28. Ericson K, Lilja A, Bergström M, et al. Positron emission tomography with ([11C] methyl)-L-methionine, [11C]D-glucose, and [68Ga]EDTA in supratentorial tumors. J Comput Assist Tomogr. 1985;9(4):683-689. (Pubitemid 15008674)
29. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995;195(1):47-52.
30. Iuchi T, Iwadate Y, Namba H, et al. Glucose and methionine uptake and proliferative activity in meningiomas. Neurol Res. 1999;21(7):640-644. (Pubitemid 29510832)
31. Liu RS, Chang CP, Guo WY, et al. 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery. J Nucl Med. 2010;51(6):883-891.
32. Lee JW, Kang KW, Park SH, et al. 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging. 2009;36(10):1574-1582.
33. Rutten I, Cabay JE, Withofs N, et al. PET/CT of skull base meningiomas using 2-18F-fluoro-L-tyrosine: initial report. J Nucl Med. 2007;48(5):720-725. (Pubitemid 47604971)
34. Grosu AL, Weber WA, Astner ST, et al. 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66(2):339-344. (Pubitemid 44332720)
35. Nyberg G, Bergström M, Enblad P, Lilja A, Muhr C, Långström B. PET-methionine of skull base neuromas and meningiomas. Acta Otolaryngol. 1997;117 (4):482-489. (Pubitemid 27359754)
36. Ogawa T, Inugami A, Hatazawa J, et al. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine. AJNR Am J Neuroradiol. 1996;17(2):345-353.
37. Astner ST, Dobrei-Ciuchendea M, Essler M, et al. Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. Int J Radiat Oncol Biol Phys. 2008;72(4): 1161-1167.
38. Giovacchini G, Fallanca F, Landoni C, et al. C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas: an initial experience. Clin Nucl Med. 2009;34(1):7-10.
39. Yeh SH, Liu RS, Wu LC, Yen SH, Chang CW, Chen KY. 11C-acetate clearance in nasopharyngeal carcinoma. Nucl Med Commun. 1999;20(2):131-134.
40. Oyama N, Akino H, Kanamaru H, et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43(2):181-186. (Pubitemid 34151040)
41. Gehler B, Paulsen F, Oksüz MO, et al. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol. 2009;4:56.
42. Henze M, Schuhmacher J, Hipp P, et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med. 2001;42(7):1053-1056. (Pubitemid 32595304)
43. Dutour A, Kumar U, Panetta R, et al. Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998;76(5):620-627. (Pubitemid 28243931)
44. Nyuyki F, Plotkin M, Graf R, et al. Potential impact of (68)Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas. Eur J Nucl Med Mol Imaging. 2010;37(2):310-318.
45. Milker-Zabel S, Zabel-du Bois A, Henze M, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65(1):222-227.
46. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20(1):22-39.
47. Jaaskelainen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol. 1986;26(5):461-469. (Pubitemid 16006137)
48. Coluccia D, Fandino J, Fujioka M, Cordovi S, Muroi C, Landolt H. Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neurochir (Wien). 2010;152(10):1711-1719.
49. Eljamel MS. Brain photodiagnosis (PD), fluorescence guided resection (FGR) and photodynamic therapy (PDT): past, present and future. Photodiagnosis Photodyn Ther. 2008;5(1):29-35.
50. Kostron H. Photodynamic diagnosis and therapy and the brain. Methods Mol Biol. 2010;635:261-280.
51. Derome PJ. Surgical management of tumours invading the skull base. Can J Neurol Sci. 1985;12(4):345-347.
52. Pompili A, Derome PJ, Visot A, Guiot G. Hyperostosing meningiomas of the sphenoid ridge-clinical features, surgical therapy, and long-term observations: review of 49 cases. Surg Neurol. 1982;17(6):411-416. (Pubitemid 12074709)
53. Derome PJ, Guiot G. Bone problems in meningiomas invading the base of the skull. Clin Neurosurg. 1978;25:435-451.
54. Derome P. [Spheno-ethmoidal tumors. Possibilities for exeresis and surgical repair]. Neurochirurgie. 1972;18(1):suppl 1):1-164.
55. Guiot G, Derome P. [Apropos of meningiomas "en plaque" of the pterion. Surgical treatment of hyperostotic osseous meningiomas]. Ann Chir. 1966;20(19): 1109-1127.
56. Guermazi A, Lafitte F, Miaux Y, Adem C, Bonneville JF, Chiras J. The dural tail sign-beyond meningioma. Clin Radiol. 2005;60(2):171-188.
57. Castellano F, Guidetti B, Olivecrona H. Pterional meningiomas en plaque. J Neurosurg. 1952;9(2):188-196.
58. Piroth MD, Pinkawa M, Holy R, et al. Prognostic value of early [18F] fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2010;80(1):176-184.
59. Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96(2):211-217.
60. Nestle U, Kremp S, Schaefer-Schuler A, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med. 2005;46(8): 1342-1348. (Pubitemid 43733485)
61. Lau EW, Drummond KJ, Ware RE, et al. Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci. 2010;17(1):43-49.
62. Astner ST, Bundschuh RA, Beer AJ, et al. Assessment of tumor volumes in skull base glomus tumors using Gluc-Lys[(18)F]-TOCA positron emission tomography. Int J Radiat Oncol Biol Phys. 2009;73(4):1135-1140.
63. Jacobs AH, Li H, Winkeler A, et al. PET-based molecular imaging in neuroscience. Eur J Nucl Med Mol Imaging. 2003;30(7):1051-1065. (Pubitemid 37086952)
64. Ebenhan T, Honer M, Ametamey SM, et al. Comparison of [18F]-tracers in various experimental tumor models by PET imaging and identification of an early response biomarker for the novel microtubule stabilizer patupilone. Mol Imaging Biol. 2009;11(5):308-321.
65. Meewes C, Bohuslavizki KH, Krisch B, Held-Feindt J, Henze E, Clausen M. Molecular biologic and scintigraphic analyses of somatostatin receptor-negative meningiomas. J Nucl Med. 2001;42(9):1338-1345. (Pubitemid 32852608)
66. Thorwarth D, Henke G, Müller AC, et al. Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience. Int J Radiat Oncol Biol Phys. 2011;81(1):277-283.
67. Boss A, Bisdas S, Kolb A, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med. 2010;51(8):1198-1205.
68. Townsend DW. Dual-modality imaging: combining anatomy and function. J Nucl Med. 2008;49(6):938-955. (Pubitemid 351793435)
69. Townsend DW, Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol. 2002;75 Spec No:S24-S30. (Pubitemid 35446444)
70. Pichler BJ, Kolb A, Nägele T, Schlemmer HP. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med. 2010; 51(3):333-336.
71. Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang ZJ, Långström B. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res. 2001;7(8):2269-2276. (Pubitemid 32751624)